Helen Myint

1. Introduction Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic beta-cells, resulting in absolute insulin deficiency [1,2]. Managing T1D is complex and requires lifelong treatment, including careful dietary management, blood glucose monitoring, and insulin replacement [3,4]. The global incidence of T1D has been rising, with New Zealand also witnessing an increasing trend [5].

Sustained clinical response to infliximab in refractory Cronkhite-Canada syndrome Caroline Di Jiang1, Helen Myint2, Andy Tie3 and Nigel H Stace4 1Gastroenterology, Wellington Hospital, Wellington, New Zealand 2Gastroenterology, Auckland City Hospital, Auckland, New Zealand 3Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand 4Department of Medicine, University of Otago, Wellington, New Zealand Correspondence to Dr Caroline Di Jiang;...